Cempra is a clinical-stage pharmaceutical company focused on
the development of antibacterial products to meet critical medical needs in the
treatment of infectious bacterial diseases. The company’s product pipeline
includes two leading candidates in advanced clinical development.
Solithromycin, Cempra’s first candidate, is currently being evaluated in phase
III clinical studies for the treatment of community acquired bacterial
pneumonia (CABP) and uncomplicated bacterial urethritis caused by Neisseria gonorrhea
and chlamydia. Taksta™, Cempra’s second candidate, is being developed for
chronic oral treatment of refractory infections in bones and joints.
Additionally, with funding provided by the Biomedical
Advanced Research Development Authority (BARDA), Cempra is currently conducting
a phase Ib clinical trial to evaluate solithromycin as a pediatric treatment
for respiratory tract infections. This program, which was initiated earlier
this year, represents the first development of a pediatric suspension formulation
of an antibiotic for the treatment of respiratory tract infections in more than
20 years.
In the first quarter of 2015, Cempra reported positive
topline results from its initial phase III clinical trial of solithromycin for
the treatment of CABP. According to the report, the product candidate performed
on pace or better than the current standard of care in sustainability of
clinical response at all studied durations.
“Cempra is off to a great start in 2015 and I am pleased
that we have achieved enrollment of 610 patients in the… phase III clinical
trial in CABP,” Dr. Prabhavathi Fernandes, president and chief executive
officer of Cempra, stated in a news release. “Our initial commercial
preparations for solithromycin are also underway as we continue our market
research activities to assess the commercial potential for this exciting new
antibiotic.”
When commercialized, solithromycin for the treatment of CABP
should provide Cempra with a platform to realize sustainable market growth in
the future. CABP is currently one of the most commonly diagnosed bacterial
infections in the United States, with an estimated five to ten million cases
recorded each year. Because many strains of the infection have become resistant
to currently-approved antibacterial drugs, the market demand for solithromycin
is expected to be immense in the years to come.
The continued development of Cempra’s advanced product
pipeline should provide channels for the company to realize improved investor
returns. For prospective shareholders, this potential makes Cempra an
intriguing investment opportunity in the months ahead. Look for the company to
continue making strides toward the eventual commercialization of its leading
product candidates in order to bolster its financial growth moving forward.
For more information, visit www.cempra.com
About
MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
